The first cases using Tetrous’ EnFix ACL reconstruction system were completed in the U.S. and Australia, according to an April 7 news release.
EnFix ACL is a 100% demineralized bone fiber implant that also utilizes the FormLok shape retention to target historical weaknesses of conventional ACL reconstruction. It is designed to promote biological regeneration at the bone graft interface and integrates into the existing ACL reconstruction procedure.
“The impetus behind EnFix ACL’s development was a direct response to ‘Enthesis Failure Syndrome’, a pervasive issue characterized by poor healing at bone-tendon or bone-graft interfaces that contributes to high failure rates in numerous soft-tissue repairs,” Andrew Carter, PhD, cofounder, director and CTO of Tetrous, said in the release. “This new product is a strategic expansion of our established EnFix technology, leveraging its proven success in shoulder applications and bringing enhanced regenerative capabilities to a wider spectrum of orthopedic challenges.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.